Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina Inc (ILMN), a global leader in genomic sequencing technologies, provides critical tools advancing precision medicine and life science research. This dedicated news hub offers investors and industry professionals centralized access to official press releases, financial disclosures, and strategic updates directly from the company.
Track developments across key areas including quarterly earnings, sequencing platform innovations, and global health partnerships. Stay informed about regulatory milestones, product launches, and collaborations shaping the future of genomic analysis. Bookmark this page for unfiltered access to Illumina's latest announcements, enabling data-driven decisions in the rapidly evolving biotechnology sector.
Illumina (NASDAQ: ILMN) announced new product developments at the AGBT General Meeting, held from June 6–9 in Orlando, Florida. Key highlights include the introduction of 2x300 base pair read lengths on NextSeq 1000 and 2000 systems, aimed at enhancing applications like metagenomics. Data showcasing the Infinity technology will be presented, emphasizing its performance in genomic mapping and structural variants. Illumina also plans sessions on genomics innovation and better informatics solutions, reflecting its commitment to driving advancements in personalized medicine.
GRAIL announced the presentation of the NHS-Galleri trial study design at the 2022 ASCO Annual Meeting. This randomized trial aims to evaluate the Galleri multi-cancer early detection test alongside standard screenings for early cancer diagnosis. Enrolling 140,000 healthy volunteers in the UK, the trial seeks to determine if the test can diagnose stage 3 and 4 cancers earlier, potentially improving survival rates. Initial results are expected in 2024, with further rollout planned if successful.
Ochsner Health announces a partnership with GRAIL to offer the Galleri multi-cancer early detection test in Louisiana. This initiative aims to enhance cancer detection rates among underserved populations through a three-year Health Equity Demonstration Program. The program will identify educational gaps and improve awareness on early cancer detection. Ochsner will also enroll participants in the PATHFINDER 2 study, targeting 20,000 individuals to evaluate the test's effectiveness. Galleri can detect signals from over 50 cancer types, with a remarkable accuracy rate of 89% in pinpointing cancer origin.
Illumina, a leader in DNA sequencing, announced the acceptance of seven oncology research abstracts for the ASCO annual meeting from June 3-7, 2022, in Chicago. The focus is on comprehensive genomic profiling (CGP) which enhances patient care by matching patients with effective therapies. Key data shows CGP identified actionable biomarkers at 45% compared to 19% for small panels. Collaborations with various health systems aim to advance cancer diagnostics, including a notable partnership with Bayer for a companion diagnostic for NTRK fusion cancer. These findings underscore the potential of CGP in personalized cancer care.
AstraZeneca has partnered with GRAIL to develop companion diagnostic (CDx) assays that will help identify patients with high-risk, early-stage cancer. This collaboration aims to enhance clinical trial recruitment and provide critical information for early-stage cancer treatment. GRAIL's methylation platform will be used in these efforts, with plans for regulatory approvals for liquid biopsy diagnostics. The partnership reflects a commitment to improving patient outcomes in oncology by leveraging innovative blood-based detections.
GRAIL, LLC has partnered with the U.S. Department of Veterans Affairs to offer the Galleri multi-cancer early detection test to 10,000 veterans across 10 sites over three years, starting with the VA Pittsburgh Healthcare System. This collaboration is part of the REFLECTION study, which aims to evaluate the test's performance alongside traditional screenings. The Galleri test can identify signals from over 50 cancer types, which is crucial for earlier and potentially curative treatment.
Illumina has announced the CE-marking of its TruSight™ Oncology Comprehensive (EU) test as the first companion diagnostic for Bayer's VITRAKVI® (larotrectinib) targeting NTRK fusion cancer patients. This comprehensive genomic profiling test can identify multiple tumor gene fusions across various solid tumor types, enhancing patient access to precision therapies. The CDx claim stems from extensive clinical validation involving data from three pivotal trials that support the efficacy of larotrectinib in eligible patients. Illumina plans to expand its CDx offerings through partnerships in oncology.
Illumina (NASDAQ: ILMN) has partnered with Allegheny Health Network (AHN) to evaluate in-house comprehensive genomic profiling (CGP) to enhance cancer care. The collaboration will analyze the effectiveness of blood-based testing compared to traditional tissue samples in identifying genetic variations that affect treatment choices. The study will involve around 1,000 samples across 24 oncology clinics. The project aims to improve patient outcomes by facilitating personalized therapy, with a focus on less invasive procedures. The initiative commenced in 2022 and is expected to last one year.
GRAIL, LLC, in collaboration with Intermountain Healthcare, is introducing the Galleri® multi-cancer early detection blood test, aimed at enhancing cancer care through early detection. Starting this month, eligible patients over 50 or with heightened cancer risk factors will have access to the test. Galleri can detect signals from over 50 cancer types, many of which lack standard screenings, boasting a low false positive rate of under 1%. This partnership aims to advance screening capabilities, reflecting a commitment to proactive cancer care.
A comprehensive analysis of 2 million Medicare beneficiaries reveals that the cost of cancer rises significantly with later diagnosis. Conducted by PHAR and GRAIL, the study indicates that late-stage cancer diagnosis can be up to seven times costlier and that these elevated costs persist for at least five years. Annual cancer care expenses total $1 trillion, highlighting the economic impact of late detection. This research provides crucial insights for healthcare professionals and emphasizes the importance of early diagnosis to mitigate costs.
